Island Pharmaceuticals Ltd (ASX:ILA) CEO Dr David Foster tells Proactive the company has officially commenced screening subjects for the ISLA-101 single ascending dose study. The company plans to repurpose ISLA-101, a well-established drug, for the prevention and treatment of dengue and other mosquito-borne diseases, addressing a significant global health concern. Three cohorts of healthy subjects will receive escalating doses of the drug to determine if these doses can safely achieve the required blood concentrations to combat the dengue virus. Dengue fever, a viral infection transmitted by infected mosquitoes, has seen a staggering increase in reported cases worldwide.
Island Pharma one step closer to ISLA-101 dosing
